Yu, L <br/><br/>
Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1.  [electronic resource] 

 -  Diabetes  Aug 2001 
 - 1735-40 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0012-1797 
<br/><br/><label>Standard No.: </label>10.2337/diabetes.50.8.1735  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Analysis of Variance<br/>Autoantibodies--blood<br/>Child<br/>Child, Preschool<br/>Clinical Trials as Topic--methods<br/>Diabetes Mellitus, Type 1--drug therapy<br/>Ethnicity<br/>Family<br/>Female<br/>Glutamate Decarboxylase--immunology<br/>HLA-DQ Antigens--genetics<br/>Humans<br/>Infant<br/>Insulin--blood<br/>Insulin Antibodies--blood<br/>Insulin Secretion<br/>Isoenzymes--immunology<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic--methods<br/>Patient Selection<br/>Predictive Value of Tests<br/>Reproducibility of Results<br/>United States